JPMorgan Downgrades Pliant Therapeutics Amid Strategic Uncertainty
JPMorgan cuts Pliant Therapeutics to Underweight rating as the biotech company searches for direction after discontinuing its main drug program earlier this year.
/ 1 item
#PLRX↓